Who benefits most from annual screening?
The strongest evidence here supports screening for specific conditions in people with known risk factors, not blanket annual checkups for everyone. For chronic kidney disease, a 2023 cost-effectiveness analysis found that screening adults for albuminuria (a key marker of kidney damage) once at age 55 was cost-effective, and screening every 10 years from ages 35 to 75 could prevent an estimated 398,000 cases of kidney failure requiring dialysis or transplant across the U.S. [3]. That means for every 1,000 people screened repeatedly over decades, roughly 3 to 4 would avoid end-stage kidney disease — a meaningful benefit for a serious condition.
For lung cancer, a 2023 study of 6,495 heavy smokers enrolled in screening trials found that those who underwent low-dose CT screening had 12-year lung cancer survival rates of 72% in women and 52% in men, with the majority diagnosed at stage I (58% of women, 51% of men) [4]. This suggests that annual screening in high-risk groups (heavy smokers) catches cancer early, when it's more treatable. However, this benefit only applies to people who meet smoking-related criteria — not the general population.
What about general health screenings like chest CT or blood tests?
Even when screening finds something, it doesn't always lead to better outcomes. A 2022 study of 2,765 adults over 50 who underwent chest CT as part of a health screening found that 3% had interstitial lung abnormalities (ILAs) — subtle lung changes that can signal early disease. Over 12 years, those with fibrotic ILAs had a 2.5 times higher risk of death from any cause and a 4.4 times higher risk of developing lung cancer compared to those without ILAs [2]. While this shows screening can detect serious conditions early, it also raises the question of what to do with that information: 80% of those with ILAs showed progression over 8 years, yet there's no proven treatment to stop it. So finding a problem doesn't guarantee you can fix it.
Similarly, a 2023 study on IgA nephropathy (a kidney disease) found that even patients traditionally considered 'low risk' (with modest protein in their urine) had high rates of kidney failure within 10 years — about 20% of those with very low protein levels still progressed to kidney failure [1]. This suggests that screening can identify people at risk, but the condition may progress despite early detection.
The catch: screening isn't harmless, and it doesn't work for everything
Annual screening can lead to overdiagnosis, unnecessary procedures, and anxiety. The lung cancer screening study noted that while screening improved survival, it also found coronary artery calcification (CAC) on scans — a marker of heart disease risk — which was higher in men (median CAC score 41) than women (median 8.7) [4]. This incidental finding might prompt further testing or treatment for heart disease, which could be beneficial or lead to unnecessary interventions. The kidney screening study explicitly modeled costs and found that one-time screening at age 55 cost $86,300 per quality-adjusted life-year (QALY) gained — a measure of value that many health systems consider borderline [3]. If the drugs used to treat early CKD (SGLT2 inhibitors) were 30% less effective, screening would no longer be cost-effective without price reductions.
Importantly, none of these studies looked at the classic 'annual physical' with blood work and a doctor's exam. The evidence here is about targeted screening for specific diseases (kidney disease, lung cancer, lung abnormalities) in defined populations. A 2023 study on COVID-19 survivors found that even mild cases increased the risk of long-term neurologic disorders like stroke and memory problems by 42% over 12 months [5], but that's about post-infection monitoring, not annual screening. The bottom line: annual screening works best when it's aimed at a specific, treatable condition in a high-risk group — not as a routine for everyone.
About These Sources
This answer is built on 5 peer-reviewed studies — published from 2022 to 2023, 5 in Q1 journals, collectively cited 949 times — selected as the most relevant from 6 studies that passed quality screening, drawn from 47 papers retrieved from a database of over 500 million.
Sources used in this answer
Long-Term Outcomes in IgA Nephropathy
In a cohort of 2,439 patients with IgA nephropathy, 50% reached kidney failure or died within a median of 5.9 years; even patients with low proteinuria (<0.44 g/g) had about a 20% risk of kidney failure within 10 years.
Prevalence and Long-term Outcomes of CT Interstitial Lung Abnormalities in a Health Screening Cohort
In a health screening cohort of 2,765 adults over 50, 3% had interstitial lung abnormalities (ILAs) on CT; those with fibrotic ILAs had a 2.5 times higher risk of all-cause mortality and a 4.4 times higher risk of lung cancer over 12 years.
Population-Wide Screening for Chronic Kidney Disease
A cost-effectiveness model found that one-time screening for chronic kidney disease at age 55 cost $86,300 per QALY gained, and screening every 10 years from ages 35-75 could prevent 398,000 cases of kidney failure requiring dialysis or transplant in the U.S.
Long-term outcomes of lung cancer screening in males and females
In 6,495 heavy smokers in lung cancer screening trials, 12-year all-cause mortality was 4.1% in women vs 7.7% in men, and lung cancer survival was 72.3% in women vs 51.7% in men, with similar rates of stage I diagnosis.
Long-term neurologic outcomes of COVID-19
In a cohort of 154,068 COVID-19 patients, the risk of any neurologic sequela at 12 months was 42% higher than in controls, with an excess burden of 70.7 events per 1,000 persons, even among those not hospitalized.